Tango Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Tango Therapeutics, Inc. (TNGX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $13.32 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- Tango Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $11.68, a 304.15% increase year-over-year.
- Tango Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $2.89, a 76.16% decline year-over-year.
- Tango Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $12.12, a 125.70% increase year-over-year.
- Tango Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $5.37, a 42.32% decline year-over-year.
- Tango Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $3.23, a 70.61% decline from fiscal 2024.
- Tango Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $10.99, a 103.14% increase from fiscal 2023.
- Tango Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $5.41, a 35.44% decline from fiscal 2022.
- Tango Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $8.38, a 11.29% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.32 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $11.68 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $3.23 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $2.97 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $2.87 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $2.89 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | $10.99 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $11.48 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $11.64 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $12.12 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $5.41 10-K · filed 2024-03-18 | |||
| 2023-09-30 | $5.19 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $5.16 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $5.37 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $8.38 10-K · filed 2023-03-27 | |||
| 2022-09-30 | $8.51 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $8.88 10-Q · filed 2022-08-10 | |||
| 2022-03-31 | $9.31 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | $7.53 10-K · filed 2022-03-28 | |||
| 2021-09-30 | $6.92 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |